GALT
Galectin Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.61
+5.86%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−42.8x
Market Cap
$464.41M
MomentumView details →
1D Return
+5.86%
YTD Return
+9.50%
RSI (14)
67.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−42.8x
Market Cap
$464.41M
RSI (14)
67.1
MomentumView details →
1D Return
+5.86%
YTD Return
+9.50%
SummaryUpdated Jun 1, 2026
Galectin Therapeutics Inc. (NASDAQ:GALT) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Norcross, Georgia. Originally incorporated as Pro-Pharmaceuticals, Inc., the company changed its name to Galectin Therapeutics in May 2011 to reflect its focus on developing therapies that target galectin proteins. The company went public in 2002 and has spent over two decades developing treatments for fibrotic diseases, cancer, and other conditions through its specialized approach of inhibiting galectin-3, a protein involved in inflammation and tissue scarring processes.
Similar companies
Latest newsMore news →
Galectin Therapeutics reported financial results for the three months ended June 30, 2026, and provided a business update.21d agoGalectin Therapeutics announced that Chairman Richard E. Uihlein converted approximately $105.8 million of outstanding debt under five line of credit facilities into common stock, eliminating the debt and increasing market capitalization.31d ago